Development of Rift Valley fever virus candidate vaccines and reagents produced in Nicotiana benthamiana

 

Show simple item record

dc.contributor.advisor Rybicki, Edward P en_ZA
dc.contributor.advisor Meyers, Ann en_ZA
dc.contributor.author Mbewana, Sandiswa en_ZA
dc.date.accessioned 2017-09-28T05:29:08Z
dc.date.available 2017-09-28T05:29:08Z
dc.date.issued 2017 en_ZA
dc.identifier.citation Mbewana, S. 2017. Development of Rift Valley fever virus candidate vaccines and reagents produced in Nicotiana benthamiana. University of Cape Town. en_ZA
dc.identifier.uri http://hdl.handle.net/11427/25446
dc.description.abstract Rift Valley fever (RVF) is a haemorrhagic fever agent caused by an infection with an enveloped negative-stranded RNA Rift Valley fever virus (RVFV). It belongs to the genus Phlebovirus in the family Bunyaviridae. The virus is spread by infected mosquitoes and affects ruminants and humans, causing high numbers of neonatal fatalities in animals and occasional fatalities in humans. It is endemic to parts of Africa and the Arabian Peninsula, but is described as an emerging virus due to the wide range of mosquitoes that could spread the disease into non-endemic areas, posing serious health and agricultural problems. The disease can be prevented by vaccination, but there is currently no Food and Drug Administration-approved RVFV vaccine that can be used outside endemic areas, while there are two live attenuated vaccines available for use in endemic areas. These vaccines have the potential for reversion, and are therefore not recommended for use in countries where RVFV is not endemic. This indicates the need for more RVFV vaccine research and development. This work focused on the development of a RVFV vaccine candidate that would allow for differentiation between infected and vaccinated animals as well as humans. en_ZA
dc.language.iso eng en_ZA
dc.subject.other Molecular and Cell Biology en_ZA
dc.title Development of Rift Valley fever virus candidate vaccines and reagents produced in Nicotiana benthamiana en_ZA
dc.type Doctoral Thesis
uct.type.publication Research en_ZA
uct.type.resource Thesis en_ZA
dc.publisher.institution University of Cape Town
dc.publisher.faculty Faculty of Science en_ZA
dc.publisher.department Department of Molecular and Cell Biology en_ZA
dc.type.qualificationlevel Doctoral
dc.type.qualificationname PhD en_ZA
uct.type.filetype Text
uct.type.filetype Image
dc.identifier.apacitation Mbewana, S. (2017). <i>Development of Rift Valley fever virus candidate vaccines and reagents produced in Nicotiana benthamiana</i>. (Thesis). University of Cape Town ,Faculty of Science ,Department of Molecular and Cell Biology. Retrieved from http://hdl.handle.net/11427/25446 en_ZA
dc.identifier.chicagocitation Mbewana, Sandiswa. <i>"Development of Rift Valley fever virus candidate vaccines and reagents produced in Nicotiana benthamiana."</i> Thesis., University of Cape Town ,Faculty of Science ,Department of Molecular and Cell Biology, 2017. http://hdl.handle.net/11427/25446 en_ZA
dc.identifier.vancouvercitation Mbewana S. Development of Rift Valley fever virus candidate vaccines and reagents produced in Nicotiana benthamiana. [Thesis]. University of Cape Town ,Faculty of Science ,Department of Molecular and Cell Biology, 2017 [cited yyyy month dd]. Available from: http://hdl.handle.net/11427/25446 en_ZA
dc.identifier.ris TY - Thesis / Dissertation AU - Mbewana, Sandiswa AB - Rift Valley fever (RVF) is a haemorrhagic fever agent caused by an infection with an enveloped negative-stranded RNA Rift Valley fever virus (RVFV). It belongs to the genus Phlebovirus in the family Bunyaviridae. The virus is spread by infected mosquitoes and affects ruminants and humans, causing high numbers of neonatal fatalities in animals and occasional fatalities in humans. It is endemic to parts of Africa and the Arabian Peninsula, but is described as an emerging virus due to the wide range of mosquitoes that could spread the disease into non-endemic areas, posing serious health and agricultural problems. The disease can be prevented by vaccination, but there is currently no Food and Drug Administration-approved RVFV vaccine that can be used outside endemic areas, while there are two live attenuated vaccines available for use in endemic areas. These vaccines have the potential for reversion, and are therefore not recommended for use in countries where RVFV is not endemic. This indicates the need for more RVFV vaccine research and development. This work focused on the development of a RVFV vaccine candidate that would allow for differentiation between infected and vaccinated animals as well as humans. DA - 2017 DB - OpenUCT DP - University of Cape Town LK - https://open.uct.ac.za PB - University of Cape Town PY - 2017 T1 - Development of Rift Valley fever virus candidate vaccines and reagents produced in Nicotiana benthamiana TI - Development of Rift Valley fever virus candidate vaccines and reagents produced in Nicotiana benthamiana UR - http://hdl.handle.net/11427/25446 ER - en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record